
Applus prices shares at €14.50
Carlyle-backed Applus has fixed its share price for its upcoming IPO at €14.50, enabling the company to raise €300m as originally planned.
At the end of last month, Applus set its share price range at €13.25-16.25 per share. The fixed price follows further evaluation of current market conditions and the completion of the book building period.
The IPO will see more than 20 million new shares offered for subscription with a nominal value of €0.10 per share and with an issue premium of €14.40 per share. The offering represents 15.9% of Applus's share capital. The offer for sale will comprise more than 55 million shares with the same nominal value, representing 42.4% stake of the company, expected to generate €800m, and will be available following the IPO.
Morgan Stanley and UBS are joint global coordinators for the IPO. Morgan Stanley, UBS, Citigroup and JP Morgan are the joint bookrunners.
Carlyle will hold onto a significant stake following the initial offering. The buyout house currently owns 68.3% of Applus, following a €1.48bn buyout in 2007. Investindustrial entered the firm's shareholding later that year, taking a 5% stake in a €20m deal. The company is the sole minority investment in Investindustrial's portfolio.
In 2005, Sociedad de Promoción y Participación Empresarial Caja Madrid, the private equity arm of Caja Madrid, injected €133m into Applus in exchange for a 19% stake in the firm, a deal which saw Grupo Agbar and Unión Fenosa reduce their shareholding in the company.
Applus specialises in testing, inspection and certification, serving clients across all industries to ensure assets and products comply with regulations, including environmental, quality, health and safety rules. In 2013, the company generated turnover of €1.6bn. Applus employs 19,000 people and is present in 60 countries.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater